Go Pro
→ Your withdrawal order could cost you in taxes (From SmartAsset) (Ad)tc pixel Free POAI Stock Alerts

Predictive Oncology (POAI) Financials

Predictive Oncology logo
$6.87 +0.11 (+1.63%)
As of 07/17/2026
Compare
Annual Income Statements for Predictive Oncology

Annual Income Statements for Predictive Oncology

This table shows Predictive Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.79 -6.53 -6.00 -10 -20 -26 -20 -26 -14 -13 -233
Consolidated Net Income / (Loss)		 -4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -14 -13 -233
Net Income / (Loss) Continuing Operations		 -4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -12 -10 -233
Total Pre-Tax Income 		-4.79 -6.53 -6.06 -8.30 -19 -26 -20 -26 -12 -10 -233
Total Operating Income		 -4.40 -6.53 -6.05 -7.86 -23 -25 -20 -26 -12 -10 -181
Total Gross Profit		 0.35 0.27 0.51 1.00 0.88 0.81 0.93 1.00 1.02 0.01 0.05
Total Revenue		 0.65 0.46 0.65 1.41 1.41 1.25 1.42 1.51 1.63 0.08 0.13
Operating Revenue		 0.65 0.46 0.65 1.41 1.41 1.25 1.42 1.51 1.63 0.08 0.13
Total Cost of Revenue		 0.30 0.18 0.15 0.42 0.53 0.45 0.49 0.51 0.61 0.08 0.07
Operating Cost of Revenue		 0.30 0.18 0.15 0.42 0.53 0.45 0.49 0.51 0.61 0.08 0.07
Total Operating Expenses		 4.75 6.80 6.56 8.86 24 26 21 27 13 10 181
Selling, General & Admin Expense		 4.25 6.33 5.47 6.49 13 13 14 15 12 7.24 26
Marketing Expense		 0.50 0.47 1.10 2.37 1.91 0.58 0.77 1.36 1.49 0.83 0.41
Research & Development Expense		 - - - - - - - - - 2.24 2.15
Other Operating Expenses / (Income)		 - - - - - - - - - 0.00 152
Total Other Income / (Expense), net		 -0.39 -0.00 -0.00 -0.44 3.69 -0.52 0.11 0.30 0.17 0.09 -52
Other Income / (Expense), net		 - - -0.00 -0.44 4.21 1.47 0.11 0.30 0.17 0.09 -52
Other Gains / (Losses), net		 - - 0.05 -1.78 -0.44 - - -0.01 -0.06 -0.01 -0.01
Net Income / (Loss) Discontinued Operations		 - - - - - - - - -1.97 -2.44 -0.24
Basic Earnings per Share		 ($30.86) ($2.31) ($0.94) ($7.87) $6.86 $2.21 ($0.36) ($6.98) ($3.48) ($34.83) ($13.37)
Weighted Average Basic Shares Outstanding		 155.23K 2.82M 6.36M 1.28M 2.87M 11.95M 54.88M 3.69M 4.01M 363.58K 17.43M
Weighted Average Diluted Shares Outstanding		 155.23K 2.82M 6.36M 1.28M 2.87M 11.95M 54.88M 79.40M 4.06M 8.93M 5.54M
Weighted Average Basic & Diluted Shares Outstanding		 155.23K 2.82M 6.36M 1.28M 2.87M 11.95M 54.88M 79.40M 4.06M 8.93M 5.54M

Quarterly Income Statements for Predictive Oncology

This table shows Predictive Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.16 -3.48 -4.22 -3.18 -3.09 -2.17 -2.44 -2.07 -78 -151 -7.71
Consolidated Net Income / (Loss)		 -3.16 -3.48 -4.22 -3.18 -3.09 -2.17 -2.44 -2.07 -78 -151 -7.71
Net Income / (Loss) Continuing Operations		 -2.75 -1.92 -3.56 -2.46 -2.13 -2.07 -2.29 -1.98 -78 -151 -7.71
Total Pre-Tax Income 		-2.74 -1.87 -3.56 -2.46 -2.12 -2.07 -2.28 -1.98 -78 -151 -7.71
Total Operating Income		 -2.74 -1.95 -3.58 -2.46 -2.16 -2.10 -2.29 -2.66 -3.28 -173 -7.73
Total Gross Profit		 0.58 -0.01 -0.02 0.05 -0.01 -0.02 0.07 -0.02 -0.00 0.01 0.03
Total Revenue		 0.68 0.22 0.00 0.07 0.00 0.01 0.11 0.00 0.00 0.01 0.04
Operating Revenue		 0.68 0.22 0.00 0.07 0.00 0.01 0.11 0.00 0.00 0.01 0.04
Total Cost of Revenue		 0.10 0.23 0.02 0.01 0.01 0.03 0.05 0.02 0.01 0.00 0.01
Operating Cost of Revenue		 0.10 0.23 0.02 0.01 0.01 0.03 0.05 0.02 0.01 0.00 0.01
Total Operating Expenses		 3.32 1.94 3.56 2.52 2.15 2.07 2.35 2.64 3.28 173 7.76
Selling, General & Admin Expense		 2.98 1.75 2.33 1.83 1.55 1.54 1.83 1.88 2.61 20 2.91
Marketing Expense		 0.33 0.35 0.61 0.13 0.07 0.02 0.00 0.27 0.13 0.00 0.01
Research & Development Expense		 - - 0.63 0.56 0.54 0.52 0.52 0.50 0.53 0.60 0.55
Other Operating Expenses / (Income)		 - - - - - - 0.00 - - - 4.30
Total Other Income / (Expense), net		 0.00 0.08 0.02 0.01 0.04 0.03 0.00 0.68 -74 22 0.02
Other Income / (Expense), net		 0.00 0.08 0.02 0.01 0.04 0.03 0.00 0.68 -74 22 0.02
Other Gains / (Losses), net		 -0.01 -0.05 -0.00 -0.00 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Net Income / (Loss) Discontinued Operations		 -0.42 - -0.65 -0.72 -0.96 -0.10 -0.16 -0.09 -0.01 0.01 0.00
Basic Earnings per Share		 ($0.78) ($0.87) ($1.04) ($0.68) ($7.26) ($5.97) ($5.12) ($0.23) ($107.25) ($8.66) ($0.36)
Weighted Average Basic Shares Outstanding		 4.03M 4.01M 4.06M 4.66M 426.42K 363.58K 476.84K 9.11M 724.00K 17.43M 21.18M
Weighted Average Diluted Shares Outstanding		 4.06M 4.06M 4.10M 6.67M 6.67M 8.93M 8.93M 10.89M 3.39M 5.54M 10.40M
Weighted Average Basic & Diluted Shares Outstanding		 4.06M 4.06M 4.10M 6.67M 6.67M 8.93M 8.93M 10.89M 3.39M 5.54M 10.40M

Annual Cash Flow Statements for Predictive Oncology

This table details how cash moves in and out of Predictive Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.84 -3.09 -1.00 -0.60 -0.01 0.53 28 -6.13 -13 -7.99 10
Net Cash From Operating Activities		 -7.49 -4.38 -4.46 -5.29 -8.73 -12 -12 -12 -12 -10 -9.88
Net Cash From Continuing Operating Activities		 -7.49 -4.38 -4.46 -5.29 -8.73 -12 -12 -12 -12 -10 -9.88
Net Income / (Loss) Continuing Operations		 -4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -12 -10 -233
Consolidated Net Income / (Loss)		 -4.79 -6.53 -6.00 -10 -19 -26 -20 -26 -14 -13 -233
Net Income / (Loss) Discontinued Operations		 - - - - - - - - -1.97 -2.44 -0.24
Depreciation Expense		 0.08 0.08 0.07 0.15 0.70 1.02 1.34 1.31 0.24 0.13 0.13
Amortization Expense		 0.22 - 0.00 0.39 2.02 1.25 0.24 - 0.48 0.50 0.56
Non-Cash Adjustments To Reconcile Net Income		 0.89 1.62 2.66 3.38 6.06 13 7.06 11 -0.14 -0.30 168
Changes in Operating Assets and Liabilities, net		 -3.89 0.45 -1.18 0.88 1.87 -1.21 -1.19 0.87 -0.35 -0.21 54
Net Cash From Investing Activities		 -0.06 -0.42 -1.65 -1.11 -0.60 -0.17 -11 -0.48 -0.05 -0.01 -33
Net Cash From Continuing Investing Activities		 -0.06 -0.42 -1.65 -1.11 -0.60 -0.17 -11 -0.48 -0.05 -0.01 -33
Purchase of Property, Plant & Equipment		 -0.03 -0.03 -0.05 -0.18 -0.01 -0.30 -0.91 -0.42 -0.02 -0.01 0.00
Other Investing Activities, net		 0.00 -0.10 -1.88 -0.88 -0.98 0.00 -0.06 - - 0.00 -33
Net Cash From Financing Activities		 12 1.71 5.11 5.79 9.32 13 50 6.72 0.15 3.94 52
Net Cash From Continuing Financing Activities		 12 1.71 5.11 5.79 9.32 13 50 6.72 0.15 3.94 52
Repayment of Debt		 -0.93 - - 0.00 -1.15 -1.45 -4.29 0.00 -0.21 -0.43 -0.16
Repurchase of Common Equity		 - - - - - 0.00 -0.01 -0.03 -0.00 -0.87 -4.05
Issuance of Debt		 0.25 - 0.00 2.19 2.69 2.76 - 0.00 0.36 0.28 0.26
Issuance of Common Equity		 13 1.71 3.81 2.96 5.32 9.95 51 6.74 0.00 4.96 56
Other Financing Activities, net		 - - 0.00 0.65 0.12 1.69 3.44 - - 0.00 -0.06
Other Net Changes in Cash		 - - - - - - - - -1.66 -1.82 0.54
Cash Interest Paid		 - - - 0.00 0.15 0.15 0.69 0.00 0.01 0.01 0.01

Quarterly Cash Flow Statements for Predictive Oncology

This table details how cash moves in and out of Predictive Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.85 -3.19 -3.53 0.13 -2.25 -2.34 2.37 -2.60 -0.32 11 -3.87
Net Cash From Operating Activities		 -2.06 -2.72 -2.71 -2.79 -2.55 -2.05 -0.99 -3.29 -1.65 -3.94 -3.75
Net Cash From Continuing Operating Activities		 -2.06 -2.72 -2.71 -2.79 -2.55 -2.05 -0.99 -3.29 -1.65 -3.94 -3.75
Net Income / (Loss) Continuing Operations		 -1.68 -2.99 -3.56 -2.46 -2.13 -2.07 -2.29 -1.98 -78 -151 -7.71
Consolidated Net Income / (Loss)		 -3.16 -3.48 -4.22 -3.18 -3.09 -2.17 -2.44 -2.07 -78 -151 -7.71
Net Income / (Loss) Discontinued Operations		 - -0.48 -0.65 -0.72 -0.96 -0.10 -0.16 -0.09 -0.01 0.01 0.00
Depreciation Expense		 -0.21 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Amortization Expense		 - - 0.12 0.12 0.13 0.13 0.13 0.14 0.14 0.15 0.15
Non-Cash Adjustments To Reconcile Net Income		 -0.08 -0.35 -0.11 -0.02 -0.12 -0.06 -0.27 -0.68 0.36 168 4.93
Changes in Operating Assets and Liabilities, net		 -0.09 0.10 0.81 -0.48 -0.45 -0.09 1.40 -0.80 75 -22 -1.15
Net Cash From Investing Activities		 0.24 0.02 -0.00 - - -0.01 0.00 - - -33 -0.02
Net Cash From Continuing Investing Activities		 0.24 0.02 -0.00 - - -0.01 0.00 - - -33 -0.02
Purchase of Property, Plant & Equipment		 0.24 0.02 -0.00 - - -0.01 0.00 - - - -0.02
Net Cash From Financing Activities		 0.26 -0.11 -0.11 3.36 0.89 -0.20 2.50 0.73 1.33 47 -0.10
Net Cash From Continuing Financing Activities		 0.26 -0.11 -0.11 3.36 0.89 -0.20 2.50 0.73 1.33 47 -0.10
Repayment of Debt		 -0.10 -0.11 -0.11 -0.04 -0.08 -0.20 0.00 - -0.08 -0.08 -0.08
Repurchase of Common Equity		 - -0.00 0.00 -0.57 -0.30 - -0.08 -0.12 -0.04 -3.81 -0.01
Issuance of Common Equity		 - - 0.00 3.70 1.26 - 2.58 0.59 1.44 51 0.01
Other Financing Activities, net		 - - - - - - 0.00 - - - -0.02
Other Net Changes in Cash		 - -0.37 -0.71 -0.43 -0.60 -0.09 0.85 -0.03 0.00 -0.28 0.00
Cash Interest Paid		 0.01 0.00 0.00 - 0.01 0.00 0.00 - 0.00 0.00 0.00

Annual Balance Sheets for Predictive Oncology

This table presents Predictive Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5.63 2.81 3.62 3.71 22 13 44 26 14 4.97 53
Total Current Assets		 5.40 2.61 2.37 1.45 0.80 1.51 29 23 10 2.23 43
Cash & Equivalents		 4.86 1.76 0.77 0.16 0.15 0.68 28 22 8.73 0.61 11
Short-Term Investments		 0.00 0.38 0.24 - - - - - - 0.00 24
Accounts Receivable		 0.04 0.04 0.14 0.23 0.30 0.26 0.35 0.33 0.28 0.03 0.03
Prepaid Expenses		 0.27 0.15 0.29 0.32 0.16 0.29 0.51 0.53 0.51 0.32 0.28
Other Current Assets		 - - - - - - - - - 0.00 7.23
Plant, Property, & Equipment, net		 0.14 0.10 0.09 0.18 1.51 3.82 2.51 1.83 0.49 0.35 0.22
Total Noncurrent Assets		 0.09 0.10 1.17 2.08 20 7.72 12 0.54 3.85 2.40 9.90
Other Noncurrent Operating Assets		 - - - 0.00 0.73 1.51 0.98 0.29 2.70 2.20 9.90
Total Liabilities & Shareholders' Equity		 5.63 2.81 3.62 3.71 22 13 44 26 14 4.97 53
Total Liabilities		 1.52 1.88 0.93 3.66 11 10 3.51 3.97 6.15 5.18 5.17
Total Current Liabilities		 1.52 1.57 0.93 3.66 11 9.34 3.24 3.88 3.95 3.59 4.27
Short-Term Debt		 - - 0.00 - 4.80 4.43 - 0.00 0.15 0.00 0.11
Accounts Payable		 0.65 0.22 0.14 0.45 3.16 1.37 1.02 0.94 1.33 1.04 1.84
Accrued Expenses		 0.86 1.35 0.79 1.28 2.37 2.59 1.26 2.23 1.54 1.24 1.52
Current Deferred Revenue		 0.01 0.01 0.01 0.02 0.04 0.05 0.19 0.60 0.30 - 0.14
Other Current Liabilities		 - - 0.00 1.91 0.51 0.89 0.77 0.11 0.45 0.78 0.65
Total Noncurrent Liabilities		 0.00 0.31 0.00 0.00 0.27 1.08 0.27 0.09 2.19 1.58 0.90
Other Noncurrent Operating Liabilities		 0.00 0.31 - 0.00 0.27 1.08 0.27 0.09 2.14 1.56 0.90
Total Equity & Noncontrolling Interests		 4.11 0.92 2.69 0.05 11 2.64 40 22 8.27 -0.20 48
Total Preferred & Common Equity		 4.11 0.92 2.69 0.05 11 2.64 40 22 8.27 -0.20 48
Preferred Stock		 - - 0.01 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4.09 0.92 2.68 0.05 11 2.64 40 22 8.27 -0.20 48
Common Stock		 45 48 56 63 94 111 168 176 176 180 461
Retained Earnings		 -40 -47 -53 -63 -82 -108 -128 -154 -168 -180 -414

Quarterly Balance Sheets for Predictive Oncology

This table presents Predictive Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 18 11 11 7.50 5.87 3.44 3.14 45
Total Current Assets		 14 6.56 6.88 4.57 3.49 1.22 1.10 38
Cash & Equivalents		 12 5.20 5.33 3.08 3.09 0.51 0.18 6.93
Short-Term Investments		 - - - - - - - 20
Accounts Receivable		 0.54 0.51 0.39 0.46 0.06 0.02 0.03 0.66
Prepaid Expenses		 0.62 0.41 0.60 0.44 0.20 0.60 0.84 0.34
Other Current Assets		 - - - - - - - 9.44
Plant, Property, & Equipment, net		 1.39 1.09 0.91 0.40 0.32 0.28 0.25 0.22
Total Noncurrent Assets		 3.25 2.95 2.79 2.53 2.07 1.93 1.78 7.41
Other Noncurrent Operating Assets		 2.99 2.71 2.55 2.31 2.01 1.87 1.73 7.41
Total Liabilities & Shareholders' Equity		 18 11 11 7.50 5.87 3.44 3.14 45
Total Liabilities		 6.52 6.55 6.49 5.53 6.01 5.09 81 4.95
Total Current Liabilities		 4.17 4.52 4.62 3.82 4.61 3.85 79 4.23
Short-Term Debt		 0.26 0.04 0.28 0.20 - 0.27 0.19 0.03
Accounts Payable		 1.17 1.73 1.56 1.14 1.21 1.35 2.72 1.35
Accrued Expenses		 1.81 1.90 1.95 1.52 2.42 1.14 1.13 1.39
Current Deferred Revenue		 0.37 0.30 0.27 0.26 0.15 0.15 0.15 0.79
Other Current Liabilities		 0.56 0.54 0.56 0.50 0.51 0.60 75 0.68
Total Noncurrent Liabilities		 2.34 2.03 1.87 1.71 1.41 1.24 1.08 0.72
Other Noncurrent Operating Liabilities		 2.34 2.03 1.87 1.71 1.41 1.24 1.08 0.72
Total Equity & Noncontrolling Interests		 12 4.05 4.09 1.97 -0.15 -1.65 -77 40
Total Preferred & Common Equity		 12 4.05 4.09 1.97 -0.15 -1.65 -77 40
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 12 4.05 4.09 1.97 -0.15 -1.65 -77 40
Common Stock		 176 176 179 180 183 183 185 462
Retained Earnings		 -164 -172 -175 -178 -183 -185 -263 -421

Annual Metrics And Ratios for Predictive Oncology

This table displays calculated financial ratios and metrics derived from Predictive Oncology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 3,312,863.00 3,804,860.00 6,282,761.00 14,091,748.00 3,887,956.00 17,676,621.00 65,576,334.00 78,753,475.00 4,063,081.00 6,666,993.00 3,393,516.00
DEI Adjusted Shares Outstanding		 44.00 1,268.00 2,094.00 4,697.00 12,960.00 58,922.00 218,588.00 262,512.00 270,872.00 444,466.00 3,393,516.00
DEI Earnings Per Adjusted Shares Outstanding		 -108,875.68 -5,146.70 -2,866.77 -2,147.43 -1,518.57 -448.71 -89.93 -98.04 -51.63 -28.49 -68.69
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -31.23% -30.24% 43.45% 115.57% -0.01% -11.28% 13.45% 5.97% 8.12% -94.79% 47.72%
EBITDA Growth		 33.25% -57.09% 7.12% -29.83% -102.17% -37.60% 13.34% -30.35% 54.02% 14.63% -2,322.08%
EBIT Growth		 31.85% -48.33% 7.19% -37.09% -122.06% -29.56% 14.94% -26.64% 53.55% 14.55% -2,179.84%
NOPAT Growth		 31.97% -48.33% 7.24% -29.86% -188.05% -11.99% 19.45% -27.44% 53.45% 14.97% -1,655.79%
Net Income Growth		 29.90% -36.23% 8.01% -68.02% -92.25% -33.49% 24.06% -30.93% 45.67% 9.44% -1,740.56%
EPS Growth		 29.90% 92.51% 59.31% -68.02% 187.17% -67.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -122.08% 41.48% -1.79% -18.57% -65.14% -40.37% 0.40% -1.33% 4.74% 14.26% 2.25%
Free Cash Flow Firm Growth		 -133.19% 41.04% -74.77% 48.01% -757.30% 74.02% -141.38% 70.68% -32.07% 15.33% -2,053.00%
Invested Capital Growth		 83.82% -64.72% 237.23% -106.47% 14,708.29% -59.71% 88.60% -102.53% -245.37% -63.07% 831.68%
Revenue Q/Q Growth		 2.75% -8.74% 14.07% 6.91% 2.61% -4.11% 14.76% -6.98% -8.05% -71.45% -92.47%
EBITDA Q/Q Growth		 -7.09% 19.22% -8.10% -27.12% -131.30% 11.53% 4.42% 2.22% 35.36% 2.96% -176.81%
EBIT Q/Q Growth		 -2.66% 19.03% -7.96% -33.15% -97.75% 10.77% 4.94% 2.24% 33.26% -1.98% -175.20%
NOPAT Q/Q Growth		 -2.66% 19.03% -7.90% -26.07% -65.50% -3.17% 16.32% 2.24% 33.15% -1.40% -1,550.82%
Net Income Q/Q Growth		 2.09% 18.99% -7.00% -29.88% -95.58% 7.19% 13.85% -0.62% 24.10% 9.35% -176.39%
EPS Q/Q Growth		 2.09% 4.94% -4.44% -29.88% 314.38% 218.18% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -53.87% 33.15% -16.92% 1.93% -22.05% 3.86% -13.37% 3.95% 4.16% 6.22% -11.48%
Free Cash Flow Firm Q/Q Growth		 -73.71% 35.29% -30.74% 52.96% -20.72% 31.67% -163.12% 65.20% 8.88% -3.42% -305.27%
Invested Capital Q/Q Growth		 61.25% 1.62% 476.66% -102.84% -22.99% -58.77% 100.60% -107.28% -30,292.89% -118.91% 116.33%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 53.54% 60.21% 77.39% 70.55% 62.32% 64.29% 65.72% 66.45% 62.57% 7.70% 42.03%
EBITDA Margin		 -626.87% -1,411.55% -914.00% -550.45% -1,112.93% -1,726.17% -1,318.64% -1,622.05% -689.80% -11,301.44% -185,303.87%
Operating Margin		 -672.36% -1,429.59% -924.43% -556.89% -1,604.23% -2,025.12% -1,437.95% -1,729.28% -744.47% -12,149.14% -144,404.49%
EBIT Margin		 -672.36% -1,429.59% -924.93% -588.19% -1,306.20% -1,907.55% -1,430.22% -1,709.27% -734.33% -12,042.15% -185,853.48%
Profit (Net Income) Margin		 -732.10% -1,429.59% -916.72% -714.51% -1,373.71% -2,066.99% -1,383.65% -1,709.62% -859.13% -14,932.31% -186,053.45%
Tax Burden Percent		 100.00% 100.00% 99.11% 121.48% 102.32% 100.00% 96.74% 100.02% 117.00% 124.00% 100.11%
Interest Burden Percent		 108.88% 100.00% 100.00% 100.00% 102.78% 108.36% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -1,858.47% -700.09% -201.06% -159.41% -154.94% -309.99% 0.00% 0.00% -2,329.42%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -1,746.71% 81.20% -358.97% -353.07% -111.11% -280.10% 0.00% 0.00% -1,748.36%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 1,526.41% -34.71% -142.60% -213.73% 63.31% 227.01% 0.00% 0.00% 1,348.27%
Return on Equity (ROE)		 682.65% -259.15% -332.06% -734.79% -343.66% -373.14% -91.62% -82.98% -93.11% -313.90% -981.16%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -424.99% 0.00% -200.53% -74.28% -216.33% 0.00% 0.00% 0.00% -1,119.20%
Operating Return on Assets (OROA)		 -134.68% -154.65% -188.34% -226.45% -141.37% -134.82% -71.51% -74.04% -59.54% -105.35% -804.84%
Return on Assets (ROA)		 -146.65% -154.65% -186.67% -275.09% -148.68% -146.09% -69.18% -74.06% -69.66% -130.63% -805.71%
Return on Common Equity (ROCE)		 691.96% -258.14% -331.32% -732.85% -342.57% -372.15% -91.62% -82.98% -93.10% -313.83% -981.12%
Return on Equity Simple (ROE_SIMPLE)		 -116.48% -706.52% -223.00% 0.00% -172.65% -979.47% -48.82% -118.25% -169.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.08 -4.57 -4.24 -5.50 -16 -18 -14 -18 -8.48 -7.21 -127
NOPAT Margin		 -470.66% -1,000.71% -647.10% -389.82% -1,122.96% -1,417.59% -1,006.56% -1,210.50% -521.13% -8,504.40% -101,083.14%
Net Nonoperating Expense Percent (NNEP)		 -86.95% -55.90% -111.76% -781.29% 157.91% 193.66% -43.82% -29.89% -35.04% -100.53% -581.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -100.72% 3,559.92% -264.80%
Cost of Revenue to Revenue		 46.46% 39.79% 22.61% 29.45% 37.68% 35.71% 34.28% 33.55% 37.43% 92.30% 57.97%
SG&A Expenses to Revenue		 648.89% 1,387.29% 834.57% 459.61% 902.64% 1,014.45% 959.45% 990.34% 715.68% 8,531.57% 20,692.47%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,642.86% 1,713.88%
Operating Expenses to Revenue		 725.91% 1,489.81% 1,001.83% 627.44% 1,666.55% 2,089.41% 1,503.67% 1,795.73% 807.04% 12,156.84% 144,446.52%
Earnings before Interest and Taxes (EBIT)		 -4.40 -6.53 -6.06 -8.30 -18 -24 -20 -26 -12 -10 -233
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.10 -6.44 -5.99 -7.77 -16 -22 -19 -24 -11 -9.58 -232
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 11.54 2.36 163.16 0.91 4.90 1.55 1.11 1.62 0.00 0.51
Price to Tangible Book Value (P/TBV)		 0.00 12.91 2.45 0.00 0.00 0.00 2.12 1.12 1.66 0.00 0.51
Price to Revenue (P/Rev)		 0.00 23.34 9.69 6.18 7.19 10.34 43.94 16.04 8.21 64.46 193.67
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 3.18 0.00 0.93 2.61 2.84 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 18.63 8.16 6.07 10.50 13.34 24.09 1.38 2.94 57.25 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.43 1.68 0.00 0.00 0.02 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 2.80 -1.39 -0.87 -0.43 0.40 0.61 -0.57 -0.81 -1.05 -1.34 -0.77
Leverage Ratio		 -4.66 1.68 1.78 2.67 2.31 2.55 1.32 1.12 1.34 2.40 1.22
Compound Leverage Factor		 -5.07 1.68 1.78 2.67 2.38 2.77 1.32 1.12 1.34 2.40 1.22
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 29.92% 62.65% 0.00% 0.00% 1.79% 0.00% 0.23%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 29.92% 62.65% 0.00% 0.00% 1.79% 0.00% 0.23%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.27% 0.00% 0.22% 0.01% 0.00% 0.00% 0.01% -0.39% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.54% 99.91% 99.73% 100.00% 69.85% 37.34% 100.00% 100.00% 98.20% 100.39% 99.77%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.31 -0.21 0.00 0.00 -0.01 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.30 -0.17 0.00 0.00 0.76 0.00 0.15
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.30 -0.25 0.00 0.00 -0.02 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.29 -0.21 0.00 0.00 1.01 0.00 0.28
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -27.12 -21.26 -30.11 -7.81 -17.53 5.81 -7.05 -17.10 -57.26 -21.78
Noncontrolling Interest Sharing Ratio		 -1.36% 0.39% 0.22% 0.26% 0.32% 0.26% 0.00% 0.00% 0.01% 0.02% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.55 1.66 2.54 0.40 0.07 0.16 9.09 6.02 2.55 0.62 10.02
Quick Ratio		 3.22 1.39 1.95 0.24 0.04 0.10 8.81 5.77 2.28 0.18 8.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.93 -4.09 -7.14 -3.71 -32 -8.27 -20 -5.85 -7.73 -6.55 -141
Operating Cash Flow to CapEx		 -23,059.11% -13,374.36% -9,890.12% -2,975.24% 0.00% -11,667.59% -1,341.01% -2,946.35% -54,725.63% -106,236.42% 0.00%
Free Cash Flow to Firm to Interest Expense		 -17.73 -1,362,330.57 0.00 0.00 -62.03 -4.14 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -19.15 -1,460,480.00 0.00 0.00 -17.01 -6.14 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -19.24 -1,471,400.00 0.00 0.00 -16.72 -6.19 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.20 0.11 0.20 0.39 0.11 0.07 0.05 0.04 0.08 0.01 0.00
Accounts Receivable Turnover		 13.66 11.83 7.42 7.63 5.33 4.52 4.65 4.39 5.35 0.54 3.78
Inventory Turnover		 1.01 0.72 0.55 1.64 2.47 1.86 1.44 1.23 1.34 0.00 0.00
Fixed Asset Turnover		 3.89 3.79 6.92 10.53 1.67 0.47 0.45 0.69 1.40 0.20 0.44
Accounts Payable Turnover		 0.21 0.42 0.82 1.42 0.30 0.20 0.41 0.51 0.54 0.07 0.05
Days Sales Outstanding (DSO)		 26.73 30.86 49.17 47.85 68.48 80.73 78.50 83.09 68.26 670.93 96.54
Days Inventory Outstanding (DIO)		 359.68 506.39 662.29 222.16 147.98 195.76 253.77 295.62 272.99 0.00 0.00
Days Payable Outstanding (DPO)		 1,708.00 874.74 444.49 257.29 1,235.86 1,847.77 897.03 710.06 682.27 5,544.72 7,250.05
Cash Conversion Cycle (CCC)		 -1,321.59 -337.49 266.97 12.71 -1,019.40 -1,571.28 -564.76 -331.35 -341.01 -4,873.80 -7,153.51
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.74 -1.22 1.68 -0.11 16 6.40 12 -0.31 -1.06 -1.72 13
Invested Capital Turnover		 -0.25 -0.46 2.87 1.80 0.18 0.11 0.15 0.26 -2.39 -0.06 0.02
Increase / (Decrease) in Invested Capital		 3.85 -0.48 2.91 -1.79 16 -9.48 5.67 -12 -0.75 -0.67 14
Enterprise Value (EV)		 0.00 8.51 5.34 8.56 15 17 34 2.08 4.79 4.86 -11
Market Capitalization		 0.00 11 6.35 8.72 10 13 62 24 13 5.47 24
Book Value per Share		 $26.37 $0.24 $0.43 $0.00 $2.88 $0.15 $0.61 $0.28 $2.04 ($0.03) $14.06
Tangible Book Value per Share		 $25.76 $0.22 $0.41 ($0.06) ($2.09) ($0.20) $0.45 $0.27 $1.98 ($0.03) $14.06
Total Capital		 4.11 0.92 2.69 0.05 16 7.07 40 22 8.42 -0.20 48
Total Debt		 0.00 0.00 0.00 0.00 4.80 4.43 0.00 0.00 0.15 0.00 0.11
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.86 -2.15 -1.01 -0.16 4.64 3.75 -28 -22 -8.58 -0.61 -35
Capital Expenditures (CapEx)		 0.03 0.03 0.05 0.18 -0.15 0.11 0.91 0.42 0.02 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.98 -1.11 0.43 -2.37 -5.43 -4.07 -1.98 -2.59 -2.45 -1.98 3.38
Debt-free Net Working Capital (DFNWC)		 3.88 1.03 1.44 -2.20 -5.28 -3.39 26 19 6.28 -1.37 39
Net Working Capital (NWC)		 3.88 1.03 1.44 -2.20 -10 -7.82 26 19 6.13 -1.37 39
Net Nonoperating Expense (NNE)		 1.71 1.96 1.77 4.58 3.54 8.13 5.36 7.51 5.50 5.45 106
Net Nonoperating Obligations (NNO)		 -4.86 -2.15 -1.01 -0.16 4.64 3.75 -28 -22 -9.33 -1.52 -35
Total Depreciation and Amortization (D&A)		 0.30 0.08 0.07 0.53 2.73 2.27 1.59 1.31 0.72 0.63 0.69
Debt-free, Cash-free Net Working Capital to Revenue		 -149.48% -244.13% 65.31% -167.62% -384.73% -324.94% -139.71% -172.32% -150.57% -2,333.76% 2,698.31%
Debt-free Net Working Capital to Revenue		 592.66% 226.50% 219.73% -156.13% -374.04% -270.77% 1,845.44% 1,293.78% 385.69% -1,612.37% 30,818.78%
Net Working Capital to Revenue		 592.66% 226.50% 219.73% -156.13% -713.79% -624.68% 1,845.44% 1,293.78% 376.45% -1,612.37% 30,732.62%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($6,150.00) ($462.00) ($244.00) ($158.00) ($137.20) $44.20 $7.20 ($7.00) ($3.48) ($34.80) ($13.37)
Adjusted Weighted Average Basic Shares Outstanding		 9.98K 32.45K 59.02K 78.96K 292.39K 2.44M 3.30M 3.65M 4.01M 363.58K 17.43M
Adjusted Diluted Earnings per Share		 ($6,150.00) ($462.00) ($244.00) ($158.00) ($137.20) $44.20 $7.20 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 9.98K 32.45K 59.02K 78.96K 292.39K 2.44M 3.30M 3.97M 4.06M 595.44K 5.54M
Adjusted Basic & Diluted Earnings per Share		 ($6,150.00) ($462.00) ($244.00) ($158.00) ($137.20) $44.20 $7.20 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 776.00 14.12K 31.82K 64.08K 143.51K 597.51K 2.74M 3.97M 4.06M 595.44K 5.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.08 -4.57 -4.24 -5.50 -9.64 -8.74 -9.43 -11 -8.48 -7.21 -127
Normalized NOPAT Margin		 -470.66% -1,000.71% -647.10% -389.82% -683.08% -697.81% -663.77% -709.91% -521.13% -8,504.40% -101,083.14%
Pre Tax Income Margin		 -732.10% -1,429.59% -924.93% -588.19% -1,342.56% -2,066.99% -1,430.22% -1,709.27% -734.33% -12,042.15% -185,853.48%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -11.26 -2,175,337.00 0.00 0.00 -35.92 -11.96 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -7.88 -1,522,735.90 0.00 0.00 -30.88 -8.89 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -11.34 -2,186,257.00 0.00 0.00 -35.63 -12.02 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -7.96 -1,533,655.90 0.00 0.00 -30.59 -8.94 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.06% -0.11% -0.01% -6.88% -1.74%

Quarterly Metrics And Ratios for Predictive Oncology

This table displays calculated financial ratios and metrics derived from Predictive Oncology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 4,028,363.00 4,063,081.00 4,062,853.00 4,101,776.00 6,666,993.00 6,666,993.00 8,931,621.00 8,931,621.00 10,892,429.00 3,393,516.00 5,539,267.00
DEI Adjusted Shares Outstanding		 268,558.00 270,872.00 270,857.00 273,452.00 444,466.00 444,466.00 595,441.00 595,441.00 726,162.00 3,393,516.00 5,539,267.00
DEI Earnings Per Adjusted Shares Outstanding		 -11.78 -12.83 -15.58 -11.63 -6.96 -4.88 -4.10 -3.48 -106.93 -44.48 -1.39
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 48.44% -39.18% -97.97% -86.28% -99.42% -96.02% 2,170.69% -96.01% -7.40% -1.34% -67.99%
EBITDA Growth		 20.97% 75.53% -7.13% 38.56% 33.28% -4.05% 37.92% 21.42% -3,840.68% -7,800.27% -255.53%
EBIT Growth		 32.61% 76.09% -4.14% 37.42% 22.35% -10.61% 35.91% 19.46% -3,555.42% -7,189.84% -237.54%
NOPAT Growth		 33.69% 75.46% -3.38% 37.75% 21.12% -7.28% 36.15% -7.92% -51.81% -8,135.84% -237.93%
Net Income Growth		 22.07% 56.10% -23.29% 18.92% 2.17% 37.57% 42.10% 34.92% -2,409.20% -6,856.60% -215.57%
EPS Growth		 0.00% 59.53% 0.00% 0.00% 0.00% 37.57% 0.00% 0.00% 0.00% -45.06% 0.00%
Operating Cash Flow Growth		 23.99% 15.80% 20.95% 21.82% -23.67% 24.61% 63.62% -17.90% 35.03% -91.95% -280.02%
Free Cash Flow Firm Growth		 312.14% -109.10% -114.92% -131.99% -131.92% -29.72% 121.76% -48.13% 10,250.12% -16,757.57% -6,960.47%
Invested Capital Growth		 -100.08% -245.37% -2,487.00% -1,537.25% -22,540.14% -63.07% -173.25% -66.88% -9,708.89% 831.68% 534.96%
Revenue Q/Q Growth		 38.06% -67.33% -97.80% 1,284.42% -94.19% 125.03% 1,154.66% -97.57% 34.90% 139.75% 307.09%
EBITDA Q/Q Growth		 21.28% 37.76% -85.98% 32.57% 14.52% 2.93% -10.96% 14.66% -4,186.69% -94.61% 95.01%
EBIT Q/Q Growth		 30.28% 31.57% -90.36% 31.10% 13.49% 2.52% -10.29% 13.41% -3,826.44% -94.40% 94.89%
NOPAT Q/Q Growth		 30.82% 28.64% -83.27% 31.19% 12.34% 2.95% -9.07% -16.30% -23.31% -5,165.12% 95.52%
Net Income Q/Q Growth		 19.37% -9.86% -21.39% 24.59% 2.72% 29.89% -12.60% 15.24% -3,650.46% -94.37% 94.89%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 42.41% -32.33% 0.52% -3.13% 8.91% 19.33% 51.99% -234.21% 49.80% -138.32% 4.95%
Free Cash Flow Firm Q/Q Growth		 -11.19% -127.05% -133.66% 43.02% 11.37% -9.94% 139.20% -487.78% 6,172.95% -282.59% 84.05%
Invested Capital Q/Q Growth		 94.08% -30,292.89% -4.74% 13.09% 18.17% -118.91% -75.50% 46.92% -4,709.80% 116.33% 4.33%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 85.54% -4.69% -361.77% 79.39% -186.08% -250.51% 59.10% -579.38% -130.96% 89.31% 80.83%
EBITDA Margin		 -435.49% -829.62% -70,211.88% -3,419.66% -50,316.61% -21,705.22% -1,919.64% -67,382.14% -2,141,200.64% -1,738,099.16% -21,320.64%
Operating Margin		 -404.80% -884.14% -73,734.75% -3,664.64% -55,296.75% -23,848.92% -2,073.29% -99,174.79% -90,654.06% -1,990,880.06% -21,887.46%
EBIT Margin		 -404.29% -846.76% -73,350.70% -3,650.57% -54,365.45% -23,550.48% -2,070.18% -73,730.20% -2,146,026.34% -1,740,147.36% -21,829.04%
Profit (Net Income) Margin		 -467.53% -1,572.09% -86,843.21% -4,730.15% -79,208.86% -24,676.91% -2,214.55% -77,198.43% -2,146,264.32% -1,740,027.96% -21,831.56%
Tax Burden Percent		 115.64% 185.66% 118.39% 129.57% 145.70% 104.78% 106.97% 104.70% 100.01% 99.99% 100.01%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -239.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,115.38% -152.28%
ROIC Less NNEP Spread (ROIC-NNEP)		 -232.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31,951.37% -136.96%
Return on Net Nonoperating Assets (RNNOA)		 208.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24,639.64% 102.42%
Return on Equity (ROE)		 -30.37% -93.11% -130.76% -149.36% -205.17% -313.90% -557.26% -801.26% 223.52% -7,475.75% -49.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,119.20% -1,115.80%
Operating Return on Assets (OROA)		 -27.88% -68.65% -5,728.81% -224.40% -1,258.61% -206.02% -47.83% -17,505.93% -671,684.55% -7,535.75% -42.97%
Return on Assets (ROA)		 -32.24% -127.46% -6,782.60% -290.76% -1,833.76% -215.88% -51.17% -18,329.40% -671,759.03% -7,535.24% -42.97%
Return on Common Equity (ROCE)		 -30.36% -93.10% -130.75% -149.35% -205.14% -313.83% -557.03% -800.74% 223.52% -7,475.50% -49.86%
Return on Equity Simple (ROE_SIMPLE)		 -158.13% 0.00% -364.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.92 -1.37 -2.51 -1.73 -1.51 -1.47 -1.60 -1.86 -2.30 -121 -5.41
NOPAT Margin		 -283.36% -618.90% -51,614.32% -2,565.25% -38,707.72% -16,694.24% -1,451.30% -69,422.36% -63,457.84% -1,393,616.04% -15,321.22%
Net Nonoperating Expense Percent (NNEP)		 -6.73% -13.42% -14.41% -14.69% -21.97% -12.94% -20.96% -8.33% -6,146.85% -164.01% -15.32%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.24% -61.28% -39.47% -69.93% 724.43% 1,098.06% 134.15% 2.97% -252.76% -13.43%
Cost of Revenue to Revenue		 14.46% 104.69% 461.77% 20.61% 286.08% 350.51% 40.90% 679.38% 230.96% 10.69% 19.17%
SG&A Expenses to Revenue		 440.91% 793.29% 47,872.87% 2,713.81% 39,551.34% 17,512.37% 1,657.33% 69,934.94% 72,224.30% 226,048.28% 8,227.24%
R&D to Revenue		 0.00% 0.00% 12,970.05% 830.71% 13,699.41% 5,885.44% 471.77% 18,632.18% 14,609.09% 6,900.44% 1,550.35%
Operating Expenses to Revenue		 490.34% 879.44% 73,372.97% 3,744.04% 55,110.67% 23,598.41% 2,132.39% 98,595.41% 90,523.11% 1,990,969.37% 21,968.29%
Earnings before Interest and Taxes (EBIT)		 -2.74 -1.87 -3.56 -2.46 -2.12 -2.07 -2.28 -1.98 -78 -151 -7.71
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.95 -1.83 -3.41 -2.30 -1.97 -1.91 -2.12 -1.81 -77 -151 -7.53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.11 1.62 2.56 1.04 2.67 0.00 0.00 0.00 0.00 0.51 0.22
Price to Tangible Book Value (P/TBV)		 1.13 1.66 2.72 1.11 3.01 0.00 0.00 0.00 0.00 0.51 0.22
Price to Revenue (P/Rev)		 7.28 8.21 7.44 4.40 17.68 64.46 71.35 4.45 6.20 193.67 178.46
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.70 2.94 3.74 0.00 7.98 57.25 55.13 4.31 6.21 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.02 0.01 0.07 0.10 0.00 0.00 -0.16 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -1.05 -1.05 -1.05 -1.06 -1.34 -2.06 -2.05 0.03 -0.77 -0.75
Leverage Ratio		 1.24 1.34 1.58 1.68 1.88 2.40 4.21 5.75 -0.14 1.22 1.27
Compound Leverage Factor		 1.24 1.34 1.58 1.68 1.88 2.40 4.21 5.75 -0.14 1.22 1.27
Debt to Total Capital		 2.18% 1.79% 0.93% 6.34% 9.05% 0.00% 0.00% -19.13% -0.24% 0.23% 0.07%
Short-Term Debt to Total Capital		 2.18% 1.79% 0.93% 6.34% 9.05% 0.00% 0.00% -19.13% -0.24% 0.23% 0.07%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.01% 0.01% 0.02% 0.02% 0.04% -0.39% -0.54% -0.06% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.81% 98.20% 99.05% 93.65% 90.91% 100.39% 100.54% 119.19% 100.24% 99.77% 99.93%
Debt to EBITDA		 -0.02 -0.01 0.00 -0.03 -0.02 0.00 0.00 -0.03 0.00 0.00 0.00
Net Debt to EBITDA		 0.67 0.76 0.43 0.47 0.29 0.00 0.00 0.03 0.00 0.15 0.11
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 -0.02 0.00 -0.04 -0.03 0.00 0.00 -0.04 -0.02 0.00 0.00
Net Debt to NOPAT		 0.92 1.01 0.60 0.67 0.41 0.00 0.00 0.03 0.00 0.28 0.21
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -11.26 -14.79 -22.51 -23.19 -33.49 -51.85 -43.75 -76.82 -228.22 -16.67 -11.63
Noncontrolling Interest Sharing Ratio		 0.00% 0.01% 0.01% 0.01% 0.01% 0.02% 0.04% 0.06% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.24 2.55 1.45 1.49 1.20 0.62 0.76 0.32 0.01 10.02 8.89
Quick Ratio		 2.99 2.28 1.26 1.24 0.93 0.18 0.68 0.14 0.00 8.26 6.58
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2.29 -0.62 -1.44 -0.82 -0.73 -0.80 0.31 -1.22 74 -135 -22
Operating Cash Flow to CapEx		 0.00% 0.00% -89,369.66% 0.00% 0.00% -31,698.13% 0.00% 0.00% 0.00% 0.00% -17,840.11%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.08 0.08 0.06 0.02 0.01 0.02 0.24 0.31 0.00 0.00
Accounts Receivable Turnover		 4.07 5.35 3.52 2.37 0.59 0.54 0.67 8.12 6.80 3.78 0.14
Inventory Turnover		 1.14 1.34 1.24 0.76 0.59 0.00 0.41 2.79 3.14 0.00 0.00
Fixed Asset Turnover		 0.98 1.40 0.97 0.79 0.33 0.20 0.27 2.79 5.07 0.44 0.19
Accounts Payable Turnover		 0.51 0.54 0.32 0.28 0.24 0.07 0.07 0.59 0.44 0.05 0.03
Days Sales Outstanding (DSO)		 89.64 68.26 103.81 153.91 619.58 670.93 546.04 44.95 53.71 96.54 2,610.03
Days Inventory Outstanding (DIO)		 320.78 272.99 293.28 480.16 617.93 0.00 881.10 130.68 116.40 0.00 0.00
Days Payable Outstanding (DPO)		 716.49 682.27 1,125.18 1,286.13 1,511.60 5,544.72 5,320.24 622.36 828.33 7,250.05 13,632.79
Cash Conversion Cycle (CCC)		 -306.06 -341.01 -728.08 -652.05 -274.09 -4,873.80 -3,893.09 -446.73 -658.22 -7,153.51 -11,022.76
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.00 -1.06 -1.11 -0.96 -0.79 -1.72 -3.02 -1.60 -77 13 13
Invested Capital Turnover		 0.84 -2.39 -2.43 -1.90 -0.75 -0.06 -0.09 -1.30 -0.04 0.02 0.01
Increase / (Decrease) in Invested Capital		 -4.20 -0.75 -1.06 -0.90 -0.78 -0.67 -1.92 -0.64 -76 14 16
Enterprise Value (EV)		 1.24 4.79 5.20 -0.79 2.37 4.86 10 7.17 10 -11 -18
Market Capitalization		 13 13 10 4.27 5.25 5.47 14 7.41 10 24 8.97
Book Value per Share		 $2.89 $2.04 $1.00 $1.00 $0.29 ($0.03) ($0.02) ($0.19) ($7.11) $14.06 $11.87
Tangible Book Value per Share		 $2.83 $1.98 $0.94 $0.94 $0.26 ($0.03) ($0.03) ($0.19) ($7.11) $14.06 $11.87
Total Capital		 12 8.42 4.09 4.37 2.16 -0.20 -0.15 -1.39 -77 48 40
Total Debt		 0.26 0.15 0.04 0.28 0.20 0.00 0.00 0.27 0.19 0.11 0.03
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -8.58 -5.16 -5.05 -2.88 -0.61 -3.09 -0.24 0.01 -35 -27
Capital Expenditures (CapEx)		 -0.24 -0.02 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.31 -2.45 -3.11 -2.79 -2.13 -1.98 -4.21 -2.86 -78 3.38 6.23
Debt-free Net Working Capital (DFNWC)		 9.61 6.28 2.08 2.54 0.95 -1.37 -1.12 -2.36 -78 39 33
Net Working Capital (NWC)		 9.35 6.13 2.04 2.27 0.75 -1.37 -1.12 -2.62 -78 39 33
Net Nonoperating Expense (NNE)		 1.25 2.11 1.71 1.46 1.58 0.70 0.84 0.21 75 30 2.30
Net Nonoperating Obligations (NNO)		 -12 -9.33 -5.16 -5.05 -2.75 -1.52 -2.88 0.05 0.30 -35 -27
Total Depreciation and Amortization (D&A)		 -0.21 0.04 0.15 0.16 0.16 0.16 0.17 0.17 0.17 0.18 0.18
Debt-free, Cash-free Net Working Capital to Revenue		 -130.29% -150.57% -223.64% -287.54% -717.82% -2,333.76% -2,213.03% -171.96% -4,709.13% 2,698.31% 12,396.94%
Debt-free Net Working Capital to Revenue		 542.84% 385.69% 149.55% 262.24% 318.57% -1,612.37% -590.24% -141.56% -4,698.21% 30,818.78% 66,406.06%
Net Working Capital to Revenue		 528.14% 376.45% 146.82% 233.68% 252.67% -1,612.37% -590.24% -157.51% -4,709.47% 30,732.62% 66,351.95%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.78) ($0.87) ($1.04) ($0.68) ($7.20) ($89.55) ($5.10) ($0.23) ($107.25) ($8.66) ($0.36)
Adjusted Weighted Average Basic Shares Outstanding		 4.03M 4.01M 4.06M 4.66M 426.42K 24.24K 476.82K 9.11M 724.00K 17.43M 21.18M
Adjusted Diluted Earnings per Share		 $0.00 ($0.87) $0.00 $0.00 $0.00 ($89.55) $0.00 $0.00 $0.00 ($8.66) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 4.06M 4.06M 4.10M 6.67M 444.47K 595.44K 595.44K 10.89M 3.39M 5.54M 10.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.87) $0.00 $0.00 $0.00 ($89.55) $0.00 $0.00 $0.00 ($8.66) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.06M 4.06M 4.10M 6.67M 444.47K 595.44K 595.44K 10.89M 3.39M 5.54M 10.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.92 -1.37 -2.51 -1.73 -1.51 -1.47 -1.60 -1.86 -2.30 -121 -5.41
Normalized NOPAT Margin		 -283.36% -618.90% -51,614.32% -2,565.25% -38,707.72% -16,694.24% -1,451.30% -69,422.36% -63,457.84% -1,393,616.04% -15,321.22%
Pre Tax Income Margin		 -404.29% -846.76% -73,350.70% -3,650.57% -54,365.45% -23,550.48% -2,070.18% -73,730.20% -2,146,026.34% -1,740,147.36% -21,829.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.13% -0.01% 0.00% -4.10% -6.25% -6.88% -8.73% -5.11% -0.29% -1.74% -1.67%

Financials Breakdown Chart

Key Financial Trends

Predictive Oncology (NASDAQ: POAI) showed a sharp improvement in revenue in Q1 2026, but the business is still losing substantial amounts of money and burning cash. The quarter also included a much stronger balance sheet than a year ago, largely because of a large increase in cash and short-term investments. However, the company remains far from profitability, and diluted share counts have fluctuated meaningfully over the period.

  • Liquidity improved materially in Q1 2026. Cash and equivalents were $6.9 million and short-term investments were $20.2 million, giving the company a much larger near-term liquidity cushion than in prior quarters.
  • Total current assets rose to $37.6 million in Q1 2026. That is a major increase from $3.4 million in Q2 2025 and $1.1 million in Q3 2025, reflecting a significantly stronger asset position.
  • Revenue improved sequentially. Q1 2026 revenue was $35.3 thousand, up from $8.7 thousand in Q4 2025 and above the very low levels seen in 2025.
  • Gross profit remained positive. Q1 2026 gross profit was $28.5 thousand, indicating revenue still exceeded direct costs.
  • Short-term debt was very small at quarter-end. Q1 2026 short-term debt was just $27.2 thousand, which is modest relative to the company’s cash and investments.
  • Operating expenses remained high relative to revenue. Q1 2026 operating expenses totaled $7.8 million, driven mainly by SG&A and other operating expenses, which dwarfed sales.
  • The company is still dependent on non-operating items and balance-sheet changes. Other income and non-cash adjustments helped offset losses in prior quarters, but this does not represent durable operating performance.
  • Share count trends remain notable. Weighted average basic shares were 21.2 million in Q1 2026, while the diluted share count was 10.4 million, suggesting ongoing capital structure complexity.
  • Q1 2026 net loss was still large. The company reported a consolidated net loss of $7.7 million, with basic EPS of $(0.36).
  • Operating cash flow was negative. Net cash from operating activities was $(3.7) million in Q1 2026, showing the core business is still consuming cash.
  • Cash burn remains a concern. Net change in cash and equivalents was $(3.9) million in Q1 2026, meaning the company continued to use cash even after financing activity.
  • Equity value has been volatile and retained earnings are deeply negative. Retained earnings stood at $(421.2) million in Q1 2026, reflecting a long history of losses.

Longer-term trend: Over the last four years, Predictive Oncology has struggled to build a stable revenue base. Quarterly revenue has generally been low and inconsistent, while operating expenses have remained far above sales. Losses have persisted every quarter in the data provided, and operating cash flow has also been negative throughout the period. The main encouraging development is the large increase in cash and short-term investments in Q1 2026, which gives the company more runway, but investors should still view the business as highly speculative until it proves it can generate sustained revenue and narrower losses.

07/18/26 01:48 PM ETAI Generated. May Contain Errors.

Predictive Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Predictive Oncology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Predictive Oncology's net income appears to be on an upward trend, with a most recent value of -$233.10 million in 2025, rising from -$4.79 million in 2015. The previous period was -$12.66 million in 2024. Find out what analysts predict for Predictive Oncology in the coming months.

Predictive Oncology's total operating income in 2025 was -$180.92 million, based on the following breakdown:
  • Total Gross Profit: $52.66 thousand
  • Total Operating Expenses: $180.97 million

Over the last 10 years, Predictive Oncology's total revenue changed from $654.35 thousand in 2015 to $125.28 thousand in 2025, a change of -80.9%.

Predictive Oncology's total liabilities were at $5.17 million at the end of 2025, a 0.1% decrease from 2024, and a 240.3% increase since 2015.

In the past 10 years, Predictive Oncology's cash and equivalents has ranged from $150.83 thousand in 2019 to $28.20 million in 2021, and is currently $10.79 million as of their latest financial filing in 2025.

Over the last 10 years, Predictive Oncology's book value per share changed from 26.37 in 2015 to 14.06 in 2025, a change of -46.7%.


Related Companies

Financial statements for NASDAQ:POAI last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
#1 Question to Ask Your Bank Today
Elon Musk's new banking platform is paying up to 15 times the national average interest rate while insuring de...
InvestorPlace | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
AI investors should get ready for a BIG surprise
Wall Street insider Jason Bodner - who called Nvidia at $4.50 - says today's most popular AI stocks are about ...
Brownstone Research | Sponsoredtc pixel
URGENT Dollar Reset Warning for Monday
A 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...
Golden Portfolio | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel